Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
B

Benralizumab

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

Yes

Subsidy Information and Financing Scheme

No

Active ingredient: Benralizumab

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

06/02/2026 Biologics as add-on therapy for severe asthma

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Benralizumab 30 mg/1 mL autoinjector pen for treating severe eosinophilic asthma; and

  • Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for treating severe allergic asthma.

Funding status

[R] Benralizumab 30 mg/ml autoinjector pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

[R] Benralizumab should be used in line with the additional clinical criteria for initiation and renewal listed in the Annex.

[R] Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes are recommended for inclusion on the Standard Drug List (SDL) from 1 April 2026.

[NR] SDL subsidy and MAF assistance do not apply to any formulations or strengths of dupilumab, mepolizumab, omalizumab reference biologic (Xolair) or tezepelumab for treating severe asthma.

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Fasenra Injection, Solution (Prefilled Syringe) 30 mg/mL

  1. Changi General Hospital

Fasenra Injection, Solution (Autoinjector Pen) 30 mg/mL

  1. Tan Tock Seng Hospital

List of monographs containing this active ingredient

Benralizumab [Fasenra]

Back to top